Table of Content

1 Report Overview
1.1 Primary Hyperoxaluria Drug Definition
1.2 Market by Type
1.2.1 Global Primary Hyperoxaluria Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 ALLN-230
1.2.3 DCR-PHXC
1.2.4 ALN-GO1
1.2.5 Others
1.3 Market Segment by Application
1.3.1 Global Primary Hyperoxaluria Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Primary Hyperoxaluria Drug Sales
2.1 Global Primary Hyperoxaluria Drug Revenue Estimates and Forecasts 2018-2034
2.2 Global Primary Hyperoxaluria Drug Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Primary Hyperoxaluria Drug Revenue by Region
2.3.1 Global Primary Hyperoxaluria Drug Revenue by Region (2018-2024)
2.3.2 Global Primary Hyperoxaluria Drug Revenue by Region (2024-2034)
2.4 Global Primary Hyperoxaluria Drug Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Primary Hyperoxaluria Drug Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Primary Hyperoxaluria Drug Sales Quantity by Region
2.6.1 Global Primary Hyperoxaluria Drug Sales Quantity by Region (2018-2024)
2.6.2 Global Primary Hyperoxaluria Drug Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Primary Hyperoxaluria Drug Sales Quantity by Manufacturers
3.1.1 Global Primary Hyperoxaluria Drug Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Primary Hyperoxaluria Drug Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Primary Hyperoxaluria Drug Sales in 2022
3.2 Global Primary Hyperoxaluria Drug Revenue by Manufacturers
3.2.1 Global Primary Hyperoxaluria Drug Revenue by Manufacturers (2018-2024)
3.2.2 Global Primary Hyperoxaluria Drug Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Primary Hyperoxaluria Drug Revenue in 2022
3.3 Global Primary Hyperoxaluria Drug Sales Price by Manufacturers
3.4 Global Key Players of Primary Hyperoxaluria Drug, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Primary Hyperoxaluria Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Primary Hyperoxaluria Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Primary Hyperoxaluria Drug, Product Offered and Application
3.8 Global Key Manufacturers of Primary Hyperoxaluria Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Primary Hyperoxaluria Drug Sales Quantity by Type
4.1.1 Global Primary Hyperoxaluria Drug Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Primary Hyperoxaluria Drug Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Primary Hyperoxaluria Drug Sales Quantity Market Share by Type (2018-2034)
4.2 Global Primary Hyperoxaluria Drug Revenue by Type
4.2.1 Global Primary Hyperoxaluria Drug Historical Revenue by Type (2018-2024)
4.2.2 Global Primary Hyperoxaluria Drug Forecasted Revenue by Type (2024-2034)
4.2.3 Global Primary Hyperoxaluria Drug Revenue Market Share by Type (2018-2034)
4.3 Global Primary Hyperoxaluria Drug Price by Type
4.3.1 Global Primary Hyperoxaluria Drug Price by Type (2018-2024)
4.3.2 Global Primary Hyperoxaluria Drug Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Primary Hyperoxaluria Drug Sales Quantity by Application
5.1.1 Global Primary Hyperoxaluria Drug Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Primary Hyperoxaluria Drug Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Primary Hyperoxaluria Drug Sales Quantity Market Share by Application (2018-2034)
5.2 Global Primary Hyperoxaluria Drug Revenue by Application
5.2.1 Global Primary Hyperoxaluria Drug Historical Revenue by Application (2018-2024)
5.2.2 Global Primary Hyperoxaluria Drug Forecasted Revenue by Application (2024-2034)
5.2.3 Global Primary Hyperoxaluria Drug Revenue Market Share by Application (2018-2034)
5.3 Global Primary Hyperoxaluria Drug Price by Application
5.3.1 Global Primary Hyperoxaluria Drug Price by Application (2018-2024)
5.3.2 Global Primary Hyperoxaluria Drug Price Forecast by Application (2024-2034)
6 North America
6.1 North America Primary Hyperoxaluria Drug Sales by Company
6.1.1 North America Primary Hyperoxaluria Drug Revenue by Company (2018-2024)
6.1.2 North America Primary Hyperoxaluria Drug Sales Quantity by Company (2018-2024)
6.2 North America Primary Hyperoxaluria Drug Market Size by Type
6.2.1 North America Primary Hyperoxaluria Drug Sales Quantity by Type (2018-2034)
6.2.2 North America Primary Hyperoxaluria Drug Revenue by Type (2018-2034)
6.3 North America Primary Hyperoxaluria Drug Market Size by Application
6.3.1 North America Primary Hyperoxaluria Drug Sales Quantity by Application (2018-2034)
6.3.2 North America Primary Hyperoxaluria Drug Revenue by Application (2018-2034)
6.4 North America Primary Hyperoxaluria Drug Market Size by Country
6.4.1 North America Primary Hyperoxaluria Drug Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Primary Hyperoxaluria Drug Revenue by Country (2018-2034)
6.4.3 North America Primary Hyperoxaluria Drug Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Primary Hyperoxaluria Drug Sales by Company
7.1.1 Europe Primary Hyperoxaluria Drug Sales Quantity by Company (2018-2024)
7.1.2 Europe Primary Hyperoxaluria Drug Revenue by Company (2018-2024)
7.2 Europe Primary Hyperoxaluria Drug Market Size by Type
7.2.1 Europe Primary Hyperoxaluria Drug Sales Quantity by Type (2018-2034)
7.2.2 Europe Primary Hyperoxaluria Drug Revenue by Type (2018-2034)
7.3 Europe Primary Hyperoxaluria Drug Market Size by Application
7.3.1 Europe Primary Hyperoxaluria Drug Sales Quantity by Application (2018-2034)
7.3.2 Europe Primary Hyperoxaluria Drug Revenue by Application (2018-2034)
7.4 Europe Primary Hyperoxaluria Drug Market Size by Country
7.4.1 Europe Primary Hyperoxaluria Drug Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Primary Hyperoxaluria Drug Revenue by Country (2018-2034)
7.4.3 Europe Primary Hyperoxaluria Drug Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Primary Hyperoxaluria Drug Sales by Company
8.1.1 China Primary Hyperoxaluria Drug Sales Quantity by Company (2018-2024)
8.1.2 China Primary Hyperoxaluria Drug Revenue by Company (2018-2024)
8.2 China Primary Hyperoxaluria Drug Market Size by Type
8.2.1 China Primary Hyperoxaluria Drug Sales Quantity by Type (2018-2034)
8.2.2 China Primary Hyperoxaluria Drug Revenue by Type (2018-2034)
8.3 China Primary Hyperoxaluria Drug Market Size by Application
8.3.1 China Primary Hyperoxaluria Drug Sales Quantity by Application (2018-2034)
8.3.2 China Primary Hyperoxaluria Drug Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Primary Hyperoxaluria Drug Sales by Company
9.1.1 APAC Primary Hyperoxaluria Drug Sales Quantity by Company (2018-2024)
9.1.2 APAC Primary Hyperoxaluria Drug Revenue by Company (2018-2024)
9.2 APAC Primary Hyperoxaluria Drug Market Size by Type
9.2.1 APAC Primary Hyperoxaluria Drug Sales Quantity by Type (2018-2034)
9.2.2 APAC Primary Hyperoxaluria Drug Revenue by Type (2018-2034)
9.3 APAC Primary Hyperoxaluria Drug Market Size by Application
9.3.1 APAC Primary Hyperoxaluria Drug Sales Quantity by Application (2018-2034)
9.3.2 APAC Primary Hyperoxaluria Drug Revenue by Application (2018-2034)
9.4 APAC Primary Hyperoxaluria Drug Market Size by Region
9.4.1 APAC Primary Hyperoxaluria Drug Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Primary Hyperoxaluria Drug Revenue by Region (2018-2034)
9.4.3 APAC Primary Hyperoxaluria Drug Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Primary Hyperoxaluria Drug Sales by Company
10.1.1 Middle East, Africa and Latin America Primary Hyperoxaluria Drug Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Primary Hyperoxaluria Drug Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Primary Hyperoxaluria Drug Market Size by Type
10.2.1 Middle East, Africa and Latin America Primary Hyperoxaluria Drug Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Primary Hyperoxaluria Drug Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Primary Hyperoxaluria Drug Market Size by Application
10.3.1 Middle East, Africa and Latin America Primary Hyperoxaluria Drug Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Primary Hyperoxaluria Drug Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Primary Hyperoxaluria Drug Market Size by Country
10.4.1 Middle East, Africa and Latin America Primary Hyperoxaluria Drug Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Primary Hyperoxaluria Drug Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Primary Hyperoxaluria Drug Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Allena Pharmaceuticals Inc
11.1.1 Allena Pharmaceuticals Inc Company Information
11.1.2 Allena Pharmaceuticals Inc Overview
11.1.3 Allena Pharmaceuticals Inc Primary Hyperoxaluria Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Allena Pharmaceuticals Inc Primary Hyperoxaluria Drug Products and Services
11.1.5 Allena Pharmaceuticals Inc Primary Hyperoxaluria Drug SWOT Analysis
11.1.6 Allena Pharmaceuticals Inc Recent Developments
11.2 Alnylam Pharmaceuticals Inc
11.2.1 Alnylam Pharmaceuticals Inc Company Information
11.2.2 Alnylam Pharmaceuticals Inc Overview
11.2.3 Alnylam Pharmaceuticals Inc Primary Hyperoxaluria Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Alnylam Pharmaceuticals Inc Primary Hyperoxaluria Drug Products and Services
11.2.5 Alnylam Pharmaceuticals Inc Primary Hyperoxaluria Drug SWOT Analysis
11.2.6 Alnylam Pharmaceuticals Inc Recent Developments
11.3 Dicerna Pharmaceuticals Inc
11.3.1 Dicerna Pharmaceuticals Inc Company Information
11.3.2 Dicerna Pharmaceuticals Inc Overview
11.3.3 Dicerna Pharmaceuticals Inc Primary Hyperoxaluria Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Dicerna Pharmaceuticals Inc Primary Hyperoxaluria Drug Products and Services
11.3.5 Dicerna Pharmaceuticals Inc Primary Hyperoxaluria Drug SWOT Analysis
11.3.6 Dicerna Pharmaceuticals Inc Recent Developments
11.4 Intellia Therapeutics Inc
11.4.1 Intellia Therapeutics Inc Company Information
11.4.2 Intellia Therapeutics Inc Overview
11.4.3 Intellia Therapeutics Inc Primary Hyperoxaluria Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Intellia Therapeutics Inc Primary Hyperoxaluria Drug Products and Services
11.4.5 Intellia Therapeutics Inc Primary Hyperoxaluria Drug SWOT Analysis
11.4.6 Intellia Therapeutics Inc Recent Developments
11.5 OxThera AB
11.5.1 OxThera AB Company Information
11.5.2 OxThera AB Overview
11.5.3 OxThera AB Primary Hyperoxaluria Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 OxThera AB Primary Hyperoxaluria Drug Products and Services
11.5.5 OxThera AB Primary Hyperoxaluria Drug SWOT Analysis
11.5.6 OxThera AB Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Primary Hyperoxaluria Drug Value Chain Analysis
12.2 Primary Hyperoxaluria Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Primary Hyperoxaluria Drug Production Mode & Process
12.4 Primary Hyperoxaluria Drug Sales and Marketing
12.4.1 Primary Hyperoxaluria Drug Sales Channels
12.4.2 Primary Hyperoxaluria Drug Distributors
12.5 Primary Hyperoxaluria Drug Customers
13 Market Dynamics
13.1 Primary Hyperoxaluria Drug Industry Trends
13.2 Primary Hyperoxaluria Drug Market Drivers
13.3 Primary Hyperoxaluria Drug Market Challenges
13.4 Primary Hyperoxaluria Drug Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Primary Hyperoxaluria Drug Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of ALLN-230
Table 3. Major Manufacturers of DCR-PHXC
Table 4. Major Manufacturers of ALN-GO1
Table 5. Major Manufacturers of Others
Table 6. Global Primary Hyperoxaluria Drug Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 7. Global Primary Hyperoxaluria Drug Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 8. Global Primary Hyperoxaluria Drug Revenue by Region (2018-2024) & (US$ Million)
Table 9. Global Primary Hyperoxaluria Drug Revenue Market Share by Region (2018-2024)
Table 10. Global Primary Hyperoxaluria Drug Revenue by Region (2024-2034) & (US$ Million)
Table 11. Global Primary Hyperoxaluria Drug Revenue Market Share by Region (2024-2034)
Table 12. Global Primary Hyperoxaluria Drug Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Pcs)
Table 13. Global Primary Hyperoxaluria Drug Sales by Region (2018-2024) & (K Pcs)
Table 14. Global Primary Hyperoxaluria Drug Sales Market Share by Region (2018-2024)
Table 15. Global Primary Hyperoxaluria Drug Sales by Region (2024-2034) & (K Pcs)
Table 16. Global Primary Hyperoxaluria Drug Sales Market Share by Region (2024-2034)
Table 17. Global Primary Hyperoxaluria Drug Sales Quantity by Manufacturers (2018-2024) & (K Pcs)
Table 18. Global Primary Hyperoxaluria Drug Sales Quantity Share by Manufacturers (2018-2024)
Table 19. Global Primary Hyperoxaluria Drug Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 20. Global Primary Hyperoxaluria Drug Revenue Share by Manufacturers (2018-2024)
Table 21. Global Primary Hyperoxaluria Drug Price by Manufacturers 2018-2024 (USD/Pcs)
Table 22. Global Key Players of Primary Hyperoxaluria Drug, Industry Ranking, 2021 VS 2022
Table 23. Global Primary Hyperoxaluria Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Primary Hyperoxaluria Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Primary Hyperoxaluria Drug as of 2022)
Table 25. Global Key Manufacturers of Primary Hyperoxaluria Drug, Manufacturing Base Distribution and Headquarters
Table 26. Global Key Manufacturers of Primary Hyperoxaluria Drug, Product Offered and Application
Table 27. Global Key Manufacturers of Primary Hyperoxaluria Drug, Date of Enter into This Industry
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Primary Hyperoxaluria Drug Sales Quantity by Type (2018-2024) & (K Pcs)
Table 30. Global Primary Hyperoxaluria Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 31. Global Primary Hyperoxaluria Drug Sales Quantity Share by Type (2018-2024)
Table 32. Global Primary Hyperoxaluria Drug Sales Quantity Share by Type (2024-2034)
Table 33. Global Primary Hyperoxaluria Drug Revenue by Type (2018-2024) & (US$ Million)
Table 34. Global Primary Hyperoxaluria Drug Revenue by Type (2024-2034) & (US$ Million)
Table 35. Global Primary Hyperoxaluria Drug Revenue Share by Type (2018-2024)
Table 36. Global Primary Hyperoxaluria Drug Revenue Share by Type (2024-2034)
Table 37. Primary Hyperoxaluria Drug Price by Type (2018-2024) & (USD/Pcs)
Table 38. Global Primary Hyperoxaluria Drug Price Forecast by Type (2024-2034) & (USD/Pcs)
Table 39. Global Primary Hyperoxaluria Drug Sales Quantity by Application (2018-2024) & (K Pcs)
Table 40. Global Primary Hyperoxaluria Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 41. Global Primary Hyperoxaluria Drug Sales Quantity Share by Application (2018-2024)
Table 42. Global Primary Hyperoxaluria Drug Sales Quantity Share by Application (2024-2034)
Table 43. Global Primary Hyperoxaluria Drug Revenue by Application (2018-2024) & (US$ Million)
Table 44. Global Primary Hyperoxaluria Drug Revenue by Application (2024-2034) & (US$ Million)
Table 45. Global Primary Hyperoxaluria Drug Revenue Share by Application (2018-2024)
Table 46. Global Primary Hyperoxaluria Drug Revenue Share by Application (2024-2034)
Table 47. Primary Hyperoxaluria Drug Price by Application (2018-2024) & (USD/Pcs)
Table 48. Global Primary Hyperoxaluria Drug Price Forecast by Application (2024-2034) & (USD/Pcs)
Table 49. North America Primary Hyperoxaluria Drug Revenue by Company (2018-2024) & (US$ Million)
Table 50. North America Primary Hyperoxaluria Drug Sales Quantity by Company (2018-2024) & (K Pcs)
Table 51. North America Primary Hyperoxaluria Drug Sales Quantity by Type (2018-2024) & (K Pcs)
Table 52. North America Primary Hyperoxaluria Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 53. North America Primary Hyperoxaluria Drug Revenue by Type (2018-2024) & (US$ Million)
Table 54. North America Primary Hyperoxaluria Drug Revenue by Type (2024-2034) & (US$ Million)
Table 55. North America Primary Hyperoxaluria Drug Sales Quantity by Application (2018-2024) & (K Pcs)
Table 56. North America Primary Hyperoxaluria Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 57. North America Primary Hyperoxaluria Drug Revenue by Application (2018-2024) & (US$ Million)
Table 58. North America Primary Hyperoxaluria Drug Revenue by Application (2024-2034) & (US$ Million)
Table 59. North America Primary Hyperoxaluria Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 60. North America Primary Hyperoxaluria Drug Revenue by Country (2018-2024) & (US$ Million)
Table 61. North America Primary Hyperoxaluria Drug Revenue by Country (2024-2034) & (US$ Million)
Table 62. North America Primary Hyperoxaluria Drug Sales Quantity by Country (2018-2024) & (K Pcs)
Table 63. North America Primary Hyperoxaluria Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 64. Europe Primary Hyperoxaluria Drug Sales Quantity by Company (2018-2024) & (K Pcs)
Table 65. Europe Primary Hyperoxaluria Drug Revenue by Company (2018-2024) & (US$ Million)
Table 66. Europe Primary Hyperoxaluria Drug Sales Quantity by Type (2018-2024) & (K Pcs)
Table 67. Europe Primary Hyperoxaluria Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 68. Europe Primary Hyperoxaluria Drug Revenue by Type (2018-2024) & (US$ Million)
Table 69. Europe Primary Hyperoxaluria Drug Revenue by Type (2024-2034) & (US$ Million)
Table 70. Europe Primary Hyperoxaluria Drug Sales Quantity by Application (2018-2024) & (K Pcs)
Table 71. Europe Primary Hyperoxaluria Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 72. Europe Primary Hyperoxaluria Drug Revenue by Application (2018-2024) & (US$ Million)
Table 73. Europe Primary Hyperoxaluria Drug Revenue by Application (2024-2034) & (US$ Million)
Table 74. Europe Primary Hyperoxaluria Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 75. Europe Primary Hyperoxaluria Drug Revenue by Country (2018-2024) & (US$ Million)
Table 76. Europe Primary Hyperoxaluria Drug Revenue by Country (2024-2034) & (US$ Million)
Table 77. Europe Primary Hyperoxaluria Drug Sales Quantity by Country (2018-2024) & (K Pcs)
Table 78. Europe Primary Hyperoxaluria Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 79. China Primary Hyperoxaluria Drug Sales Quantity by Company (2018-2024) & (K Pcs)
Table 80. China Primary Hyperoxaluria Drug Revenue by Company (2018-2024) & (US$ Million)
Table 81. China Primary Hyperoxaluria Drug Sales Quantity by Type (2018-2024) & (K Pcs)
Table 82. China Primary Hyperoxaluria Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 83. China Primary Hyperoxaluria Drug Revenue by Type (2018-2024) & (US$ Million)
Table 84. China Primary Hyperoxaluria Drug Revenue by Type (2024-2034) & (US$ Million)
Table 85. China Primary Hyperoxaluria Drug Sales Quantity by Application (2018-2024) & (K Pcs)
Table 86. China Primary Hyperoxaluria Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 87. China Primary Hyperoxaluria Drug Revenue by Application (2018-2024) & (US$ Million)
Table 88. China Primary Hyperoxaluria Drug Revenue by Application (2024-2034) & (US$ Million)
Table 89. APAC Primary Hyperoxaluria Drug Sales Quantity by Company (2018-2024) & (K Pcs)
Table 90. APAC Primary Hyperoxaluria Drug Revenue by Company (2018-2024) & (US$ Million)
Table 91. APAC Primary Hyperoxaluria Drug Sales Quantity by Type (2018-2024) & (K Pcs)
Table 92. APAC Primary Hyperoxaluria Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 93. APAC Primary Hyperoxaluria Drug Revenue by Type (2018-2024) & (US$ Million)
Table 94. APAC Primary Hyperoxaluria Drug Revenue by Type (2024-2034) & (US$ Million)
Table 95. APAC Primary Hyperoxaluria Drug Sales Quantity by Application (2018-2024) & (K Pcs)
Table 96. APAC Primary Hyperoxaluria Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 97. APAC Primary Hyperoxaluria Drug Revenue by Application (2018-2024) & (US$ Million)
Table 98. APAC Primary Hyperoxaluria Drug Revenue by Application (2024-2034) & (US$ Million)
Table 99. APAC Primary Hyperoxaluria Drug Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 100. APAC Primary Hyperoxaluria Drug Revenue by Region (2018-2024) & (US$ Million)
Table 101. APAC Primary Hyperoxaluria Drug Revenue by Region (2024-2034) & (US$ Million)
Table 102. APAC Primary Hyperoxaluria Drug Sales Quantity by Region (2018-2024) & (K Pcs)
Table 103. APAC Primary Hyperoxaluria Drug Sales Quantity by Region (2024-2034) & (K Pcs)
Table 104. Middle East, Africa and Latin America Primary Hyperoxaluria Drug Sales Quantity by Company (2018-2024) & (K Pcs)
Table 105. Middle East, Africa and Latin America Primary Hyperoxaluria Drug Revenue by Company (2018-2024) & (US$ Million)
Table 106. Middle East, Africa and Latin America Primary Hyperoxaluria Drug Sales Quantity by Type (2018-2024) & (K Pcs)
Table 107. Middle East, Africa and Latin America Primary Hyperoxaluria Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 108. Middle East, Africa and Latin America Primary Hyperoxaluria Drug Revenue by Type (2018-2024) & (US$ Million)
Table 109. Middle East, Africa and Latin America Primary Hyperoxaluria Drug Revenue by Type (2024-2034) & (US$ Million)
Table 110. Middle East, Africa and Latin America Primary Hyperoxaluria Drug Sales Quantity by Application (2018-2024) & (K Pcs)
Table 111. Middle East, Africa and Latin America Primary Hyperoxaluria Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 112. Middle East, Africa and Latin America Primary Hyperoxaluria Drug Revenue by Application (2018-2024) & (US$ Million)
Table 113. Middle East, Africa and Latin America Primary Hyperoxaluria Drug Revenue by Application (2024-2034) & (US$ Million)
Table 114. Middle East, Africa and Latin America Primary Hyperoxaluria Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 115. Middle East, Africa and Latin America Primary Hyperoxaluria Drug Revenue by Country (2018-2024) & (US$ Million)
Table 116. Middle East, Africa and Latin America Primary Hyperoxaluria Drug Revenue by Country (2024-2034) & (US$ Million)
Table 117. Middle East, Africa and Latin America Primary Hyperoxaluria Drug Sales Quantity by Country (2018-2024) & (K Pcs)
Table 118. Middle East, Africa and Latin America Primary Hyperoxaluria Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 119. Allena Pharmaceuticals Inc Company Information
Table 120. Allena Pharmaceuticals Inc Description and Overview
Table 121. Allena Pharmaceuticals Inc Primary Hyperoxaluria Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 122. Allena Pharmaceuticals Inc Primary Hyperoxaluria Drug Product and Services
Table 123. Allena Pharmaceuticals Inc Primary Hyperoxaluria Drug SWOT Analysis
Table 124. Allena Pharmaceuticals Inc Recent Developments
Table 125. Alnylam Pharmaceuticals Inc Company Information
Table 126. Alnylam Pharmaceuticals Inc Description and Overview
Table 127. Alnylam Pharmaceuticals Inc Primary Hyperoxaluria Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 128. Alnylam Pharmaceuticals Inc Primary Hyperoxaluria Drug Product and Services
Table 129. Alnylam Pharmaceuticals Inc Primary Hyperoxaluria Drug SWOT Analysis
Table 130. Alnylam Pharmaceuticals Inc Recent Developments
Table 131. Dicerna Pharmaceuticals Inc Company Information
Table 132. Dicerna Pharmaceuticals Inc Description and Overview
Table 133. Dicerna Pharmaceuticals Inc Primary Hyperoxaluria Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 134. Dicerna Pharmaceuticals Inc Primary Hyperoxaluria Drug Product and Services
Table 135. Dicerna Pharmaceuticals Inc Primary Hyperoxaluria Drug SWOT Analysis
Table 136. Dicerna Pharmaceuticals Inc Recent Developments
Table 137. Intellia Therapeutics Inc Company Information
Table 138. Intellia Therapeutics Inc Description and Overview
Table 139. Intellia Therapeutics Inc Primary Hyperoxaluria Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 140. Intellia Therapeutics Inc Primary Hyperoxaluria Drug Product and Services
Table 141. Intellia Therapeutics Inc Primary Hyperoxaluria Drug SWOT Analysis
Table 142. Intellia Therapeutics Inc Recent Developments
Table 143. OxThera AB Company Information
Table 144. OxThera AB Description and Overview
Table 145. OxThera AB Primary Hyperoxaluria Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 146. OxThera AB Primary Hyperoxaluria Drug Product and Services
Table 147. OxThera AB Primary Hyperoxaluria Drug SWOT Analysis
Table 148. OxThera AB Recent Developments
Table 149. Key Raw Materials Lists
Table 150. Raw Materials Key Suppliers Lists
Table 151. Primary Hyperoxaluria Drug Distributors List
Table 152. Primary Hyperoxaluria Drug Customers List
Table 153. Primary Hyperoxaluria Drug Market Trends
Table 154. Primary Hyperoxaluria Drug Market Drivers
Table 155. Primary Hyperoxaluria Drug Market Challenges
Table 156. Primary Hyperoxaluria Drug Market Restraints
Table 157. Research Programs/Design for This Report
Table 158. Key Data Information from Secondary Sources
Table 159. Key Data Information from Primary Sources
List of Figures
Figure 1. Primary Hyperoxaluria Drug Product Picture
Figure 2. Global Primary Hyperoxaluria Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Primary Hyperoxaluria Drug Market Share by Type in 2022 & 2034
Figure 4. ALLN-230 Product Picture
Figure 5. DCR-PHXC Product Picture
Figure 6. ALN-GO1 Product Picture
Figure 7. Others Product Picture
Figure 8. Global Primary Hyperoxaluria Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 9. Global Primary Hyperoxaluria Drug Market Share by Application in 2022 & 2034
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Others
Figure 13. Primary Hyperoxaluria Drug Report Years Considered
Figure 14. Global Primary Hyperoxaluria Drug Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 15. Global Primary Hyperoxaluria Drug Revenue 2018-2034 (US$ Million)
Figure 16. Global Primary Hyperoxaluria Drug Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 17. Global Primary Hyperoxaluria Drug Sales Quantity 2018-2034 (K Pcs)
Figure 18. Global Primary Hyperoxaluria Drug Sales Quantity Market Share by Region (2018-2024)
Figure 19. Global Primary Hyperoxaluria Drug Sales Quantity Market Share by Region (2024-2034)
Figure 20. North America Primary Hyperoxaluria Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 21. North America Primary Hyperoxaluria Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 22. Europe Primary Hyperoxaluria Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 23. Europe Primary Hyperoxaluria Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 24. China Primary Hyperoxaluria Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 25. China Primary Hyperoxaluria Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 26. APAC Primary Hyperoxaluria Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 27. APAC Primary Hyperoxaluria Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 28. Middle East, Africa and Latin America Primary Hyperoxaluria Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 29. Middle East, Africa and Latin America Primary Hyperoxaluria Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 30. The Top 10 and Top 5 Players Market Share by Primary Hyperoxaluria Drug Sales Quantity in 2022
Figure 31. The Top 10 and Top 5 Players Market Share by Primary Hyperoxaluria Drug Revenue in 2022
Figure 32. Primary Hyperoxaluria Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 33. Global Primary Hyperoxaluria Drug Sales Quantity Market Share by Type (2018-2034)
Figure 34. Global Primary Hyperoxaluria Drug Revenue Market Share by Type (2018-2034)
Figure 35. Global Primary Hyperoxaluria Drug Sales Quantity Market Share by Application (2018-2034)
Figure 36. Global Primary Hyperoxaluria Drug Revenue Market Share by Application (2018-2034)
Figure 37. North America Primary Hyperoxaluria Drug Revenue Market Share by Company in 2022
Figure 38. North America Primary Hyperoxaluria Drug Sales Quantity Market Share by Company in 2022
Figure 39. North America Primary Hyperoxaluria Drug Sales Quantity Market Share by Type (2018-2034)
Figure 40. North America Primary Hyperoxaluria Drug Revenue Market Share by Type (2018-2034)
Figure 41. North America Primary Hyperoxaluria Drug Sales Quantity Market Share by Application (2018-2034)
Figure 42. North America Primary Hyperoxaluria Drug Revenue Market Share by Application (2018-2034)
Figure 43. North America Primary Hyperoxaluria Drug Revenue Share by Country (2018-2034)
Figure 44. North America Primary Hyperoxaluria Drug Sales Quantity Share by Country (2018-2034)
Figure 45. U.S. Primary Hyperoxaluria Drug Revenue (2018-2034) & (US$ Million)
Figure 46. Canada Primary Hyperoxaluria Drug Revenue (2018-2034) & (US$ Million)
Figure 47. Europe Primary Hyperoxaluria Drug Sales Quantity Market Share by Company in 2022
Figure 48. Europe Primary Hyperoxaluria Drug Revenue Market Share by Company in 2022
Figure 49. Europe Primary Hyperoxaluria Drug Sales Quantity Market Share by Type (2018-2034)
Figure 50. Europe Primary Hyperoxaluria Drug Revenue Market Share by Type (2018-2034)
Figure 51. Europe Primary Hyperoxaluria Drug Sales Quantity Market Share by Application (2018-2034)
Figure 52. Europe Primary Hyperoxaluria Drug Revenue Market Share by Application (2018-2034)
Figure 53. Europe Primary Hyperoxaluria Drug Revenue Share by Country (2018-2034)
Figure 54. Europe Primary Hyperoxaluria Drug Sales Quantity Share by Country (2018-2034)
Figure 55. Germany Primary Hyperoxaluria Drug Revenue (2018-2034) & (US$ Million)
Figure 56. France Primary Hyperoxaluria Drug Revenue (2018-2034) & (US$ Million)
Figure 57. U.K. Primary Hyperoxaluria Drug Revenue (2018-2034) & (US$ Million)
Figure 58. Italy Primary Hyperoxaluria Drug Revenue (2018-2034) & (US$ Million)
Figure 59. Russia Primary Hyperoxaluria Drug Revenue (2018-2034) & (US$ Million)
Figure 60. China Primary Hyperoxaluria Drug Sales Quantity Market Share by Company in 2022
Figure 61. China Primary Hyperoxaluria Drug Revenue Market Share by Company in 2022
Figure 62. China Primary Hyperoxaluria Drug Sales Quantity Market Share by Type (2018-2034)
Figure 63. China Primary Hyperoxaluria Drug Revenue Market Share by Type (2018-2034)
Figure 64. China Primary Hyperoxaluria Drug Sales Quantity Market Share by Application (2018-2034)
Figure 65. China Primary Hyperoxaluria Drug Revenue Market Share by Application (2018-2034)
Figure 66. APAC Primary Hyperoxaluria Drug Sales Quantity Market Share by Company in 2022
Figure 67. APAC Primary Hyperoxaluria Drug Revenue Market Share by Company in 2022
Figure 68. APAC Primary Hyperoxaluria Drug Sales Quantity Market Share by Type (2018-2034)
Figure 69. APAC Primary Hyperoxaluria Drug Revenue Market Share by Type (2018-2034)
Figure 70. APAC Primary Hyperoxaluria Drug Sales Quantity Market Share by Application (2018-2034)
Figure 71. APAC Primary Hyperoxaluria Drug Revenue Market Share by Application (2018-2034)
Figure 72. APAC Primary Hyperoxaluria Drug Revenue Share by Region (2018-2034)
Figure 73. APAC Primary Hyperoxaluria Drug Sales Quantity Share by Region (2018-2034)
Figure 74. Japan Primary Hyperoxaluria Drug Revenue (2018-2034) & (US$ Million)
Figure 75. South Korea Primary Hyperoxaluria Drug Revenue (2018-2034) & (US$ Million)
Figure 76. China Taiwan Primary Hyperoxaluria Drug Revenue (2018-2034) & (US$ Million)
Figure 77. Southeast Asia Primary Hyperoxaluria Drug Revenue (2018-2034) & (US$ Million)
Figure 78. India Primary Hyperoxaluria Drug Revenue (2018-2034) & (US$ Million)
Figure 79. Middle East, Africa and Latin America Primary Hyperoxaluria Drug Sales Quantity Market Share by Company in 2022
Figure 80. Middle East, Africa and Latin America Primary Hyperoxaluria Drug Revenue Market Share by Company in 2022
Figure 81. Middle East, Africa and Latin America Primary Hyperoxaluria Drug Sales Quantity Market Share by Type (2018-2034)
Figure 82. Middle East, Africa and Latin America Primary Hyperoxaluria Drug Revenue Market Share by Type (2018-2034)
Figure 83. Middle East, Africa and Latin America Primary Hyperoxaluria Drug Sales Quantity Market Share by Application (2018-2034)
Figure 84. Middle East, Africa and Latin America Primary Hyperoxaluria Drug Revenue Market Share by Application (2018-2034)
Figure 85. Middle East, Africa and Latin America Primary Hyperoxaluria Drug Sales Quantity Share by Country (2018-2034)
Figure 86. Middle East, Africa and Latin America Primary Hyperoxaluria Drug Revenue Share by Country (2018-2034)
Figure 87. Brazil Primary Hyperoxaluria Drug Revenue (2018-2034) & (US$ Million)
Figure 88. Mexico Primary Hyperoxaluria Drug Revenue (2018-2034) & (US$ Million)
Figure 89. Turkey Primary Hyperoxaluria Drug Revenue (2018-2034) & (US$ Million)
Figure 90. Israel Primary Hyperoxaluria Drug Revenue (2018-2034) & (US$ Million)
Figure 91. GCC Countries Primary Hyperoxaluria Drug Revenue (2018-2034) & (US$ Million)
Figure 92. Primary Hyperoxaluria Drug Value Chain
Figure 93. Primary Hyperoxaluria Drug Production Process
Figure 94. Channels of Distribution (Direct Vs Distribution)
Figure 95. Distributors Profiles
Figure 96. Bottom-up and Top-down Approaches for This Report
Figure 97. Data Triangulation
Figure 98. Key Executives Interviewed